Second hematopoietic stem cell transplantation in myeloid malignancies

Current Opinion in Hematology

Volumn 16, Issue 2, 2009, Pages 112-123

  Arfons, Lisa M ^a   Tomblyn, Marcie ^b   Rocha, Vanderson ^c   Lazarus, Hillard M ^a,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Disease relapse; Graft failure; Myeloid malignancy; Second allogeneic stem cell transplantation; Umbilical cord blood transplantation

Indexed keywords

ANTILEUKEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD DONOR; CANCER SURVIVAL; COMORBIDITY; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UMBILICAL CORD BLOOD;

ANTIBODIES, MONOCLONAL; CORD BLOOD STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 62249143534     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283257a87     Document Type: Review

References (38)

1. Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002; 29:545-552.
2. Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant 2008; 42:297-310. This review discusses the different methods of chimerism analysis and the role of chimerism in both malignant and nonmalignant disease states. The authors also discuss the role of graft type, lineage-specific chimerism and the clinical application of the analysis.
3. Guardiola P, Kuentz M, Garban F, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anemia. Br J Haematol 2000; 111:292-302.
4. Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol 2005; 132:36-41.
5. Fernandes J, Rocha V, Robin M, et al. Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. Br J Haematol 2007; 137:248-251.
6. Jabbour E, Rondon G, Anderlini P, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 2007; 40:431-435.
7. Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007; 13:1313-1323.
8. Lang P, Mueller I, Greil J, et al. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis 2008; 40:33-39.
9. Byrne BJ, Horwitz M, Long GD, et al. Outcomes of a second nonmyeloablative allogeneic stem cell transplantation following graft rejection. Bone Marrow Transplant 2008; 41:39-43.
10. Heinzelmann F, Lang PJ, Ottinger H, et al. Immunosuppressivetotal lymphoid radiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation, Int J Radiat Oncol Biol Phys 2008; 70:523-528. This retrospective trial evaluated 14 patients with hematologic malignancies who underwent a second transplant for graft failure. The authors postulate that a total lymphoid irradiation-based conditioning regimen would be efficacious with a low-toxicity profile. The seven pediatric patients (16 years or younger) fared better than the older cohort with a DFS and OS of 85.7% each after 681 days median followup. Treatment-related toxicity was minimal without major complications. The adult cohort all died from infectious complications, GVHD, disease relapse and treatment-related complications.
11. Platzbecker U, Binder M, Schmid C, et al. Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation. Haematologica 2008; 93:1276-1278.
12. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276-2285.
13. Tse WW, Zang SL, Bunting KD, Laughlin MJ. Umbilical cord blood transplantation in adult myeloid leukemia. Bone Marrow Transplant 2008; 41:465-472. This review discusses the immunologic properties, clinical application and outcomes of umbilical cord blood transplantation.
14. Rocha V, Sanz G, Gluckman E, et al. Umbilical cord blood transplantation. Curr Opin Hematol 2004; 11:375-385.
15. Satoh N, Takenouchi S, Hashimoto S, et al. Switching of donor cells after urgent second cord blood transplantation for suspected graft failure, Int J Hematol 2007; 86:451-454.
16. Nakamura Y, Tanaka Y, Ando T, et al. Successful engraftment of the second reduced-intensity conditioning cord blood transplantation (UCBT) for a patient who developed graft rejection and infectious complications after the first UCBT for AML. Bone Marrow Transplant 2007; 40:395-396.
17. Ohwada C, Nakaseko C, Ozawa S, et al. Second cord blood transplantation (UCBT) with reduced-intensity conditioning for graft failure after the first UCBT for AML Bone Marrow Transplant 2004; 34:999-1000.
18. Frassoni F, Gualandi F, Podestà M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008; 9:831-839. This clinical trial examined the outcomes of 32 patients who underwent direct intrabone marrow cord blood transplantation. Sixteen patients were alive at a median follow-up of 13 months; there were no treatment-related complications with the method of administration. The majority of the patients had neutrophil and platelet recovery by a median time of 23 and 36 days, respectively. There was a lower rate of acute and chronic GVHD as compared to intravenous administration of cord blood. The authors postulate that intrabone marrow infusion of cord blood is an acceptable method of transplantation, and further larger studies are warranted.
19. Brunstein C, Barker J, Weisdorf D, et al. Intra-bone marrow injection of umbilical cord blood: no impact on rate of haematopoietic recovery. Bone Marrow Transplant 2008; 41:322.
20. Blau IW, Basara N, Bischoff M, et al. Second allogeneic hematopoietic stem cell transplantation as a treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 2000; 25:41-45.
21. Radich JP, Gooley T, Sanders JE, et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6:272-279.
22. Ringdén O, Labopin M, Gorin NC, et al. The dismal outcome in patients with acute leukemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Bone Marrow Transplant 2000; 25:1053-1058.
23. Devine SM, Sanborn R, Jessop E, et al. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant 2001; 28:557-562.
24. Meshinchi S, Leisenring WM, Carpenter PA, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003; 9:706-713.
25. Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24:4150-4157.
26. Grüllich C, Bertz H, Spyridonidis A, et al. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant 2008; 41:845-850.
27. Michallet M, Tanguy ML, Socié G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM). Br J Haematol 2000; 108:400-407.
28. Pawson R, Potter MN, Theocharous P, et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAGi Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115:622-629.
29. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19:3675-3684.
30. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34:721-727.
31. Duus JE, Stiff PJ, Choi J, et al. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplant 2005; 35:261-264.
32. Pollyea DA, Artz AS, Stock W, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40:1027-1032.
33. Sica RA, Vosganian GS, Tuscano JM, et al. Reduced intensity stem cell transplant (RIST) as salvage treatment for relapse following myeloablative allogeneic transplantation in adult acute myeloid leukemia [abstract 367]. Biol Blood Marrow Transplant 2007; 13:133.
34. Shaw BE, Mufti GJ, Mackinnon S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008; 42:783-789.
35. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant 2008; 42:569-579.
36. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25:4938-4945.
37. Reich-Zeliger S, Bachar-Lustig E, Bar-llan A, Reisner Y. Tolerance induction in presensitized bone marrow recipients by veto CTLs: effective deletion of host antidonor memory effector cells. J Immunol 2007; 179:6389-6394. This study examines the ability of veto cells to induce apoptosis in presensitized CDS T cells in vitro. The authors then demonstrate that in a mouse model, bone marrow veto cells also effectively overcame CDS T cells, theoretically allowing for reduced capacity of GVHD.
38. Symons HJ, Fuchs EJ. Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant 2008; 42:365-377.